Patient characteristics
Characteristic . | Patients, no. (%) . |
|---|---|
| Diagnosis | |
| Precursor B-ALL | 85 (89) |
| Mature B-ALL | 10 (11) |
| Treatment regimen | |
| Hyper-CVAD | 45 (47) |
| Hyper-CVAD plus rituximab | 38 (40) |
| Hyper-CVAD plus imatinib | 12 (13) |
| Karyotype | |
| Diploid | 28 (35) |
| Insufficient metaphases | 16 (20) |
| t(9;22) | 17 (21) |
| t(8;14), t(2;8), t(8;22) | 6 (7) |
| Hypodiploid | 8 (10) |
| Other | 6 (7) |
| Data not available | 14 |
| Antecedent hematologic abnormality | |
| Absent | 86 (93) |
| Present | 6 (7) |
| Data not available | 3 |
| Response to therapy | |
| Complete response | 91 (96) |
| No response | 4 (4) |
| ECOG performance status | |
| 2 or lower | 87 (97) |
| Greater than 2 | 3 (3) |
| Data not available | 5 |
Characteristic . | Patients, no. (%) . |
|---|---|
| Diagnosis | |
| Precursor B-ALL | 85 (89) |
| Mature B-ALL | 10 (11) |
| Treatment regimen | |
| Hyper-CVAD | 45 (47) |
| Hyper-CVAD plus rituximab | 38 (40) |
| Hyper-CVAD plus imatinib | 12 (13) |
| Karyotype | |
| Diploid | 28 (35) |
| Insufficient metaphases | 16 (20) |
| t(9;22) | 17 (21) |
| t(8;14), t(2;8), t(8;22) | 6 (7) |
| Hypodiploid | 8 (10) |
| Other | 6 (7) |
| Data not available | 14 |
| Antecedent hematologic abnormality | |
| Absent | 86 (93) |
| Present | 6 (7) |
| Data not available | 3 |
| Response to therapy | |
| Complete response | 91 (96) |
| No response | 4 (4) |
| ECOG performance status | |
| 2 or lower | 87 (97) |
| Greater than 2 | 3 (3) |
| Data not available | 5 |
N equals 95 patients. The mean age of patients was 46 years; ages ranged from 17 to 83 years.